Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Initial Phase 1 ARR-217 (MRG007) data disclosed in gastrointestinal cancer patients.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Initial Phase 1 ARR-217 (MRG007) data disclosed in gastrointestinal cancer patients
- CDH17-targeted antibody-drug conjugate presented at ESMO Congress 2026
- Clinical update may influence investor views on ARR-217’s safety, efficacy and development potential
- Full study results available in Exhibit 99.1
Item 8.01 · Other Events
- Item 8.01 incorporates most of the Item 7.01 press release into the filing
- Investor significance depends on the underlying press release, which contains the substantive event details
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 ARR-217 data showed 44.8% ORR and 93.1% DCR at 6 mg/kg Q3W in pretreated CRC patients
- Activity extended across doses: 34.2% ORR and 91.8% DCR at 4 mg/kg Q3W and higher
- Safety generally manageable, with Grade 3+ treatment-related events in 20.4% of patients at 6 mg/kg
- No Grade 5 treatment-related adverse events or interstitial lung disease observed
- Phase 1b dose optimization underway at 5 and 6 mg/kg Q3W, with data expected in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.